Acute Pancreatitis News and Research RSS Feed - Acute Pancreatitis News and Research

Acute pancreatitis is a sudden inflammation of the pancreas. Depending on its severity, it can have severe complications and high mortality despite treatment. While mild cases are often successfully treated with conservative measures, such as NPO (nil by mouth or NBM) and IV fluid rehydration, severe cases may require admission to the ICU or even surgery (often requiring more than one intervention) to deal with complications of the disease process.
Special issue of Gastroenterology presents variety of topics related to pancreas

Special issue of Gastroenterology presents variety of topics related to pancreas

The editors of Gastroenterology, the official journal of the American Gastroenterological Association Institute, are pleased to announce the publication of this year's highly anticipated special 13th issue. [More]
Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Acute pancreatitis is an inflammation of the pancreas which leads to leakage of pancreatic enzymes. Apart from certain drugs such as GLP-1 based therapies, the most common causes of pancreatitis are Gallstones and Alcohol use. [More]
Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes. [More]
New study associates commonly used diabetes drugs with pancreatic cancer risk

New study associates commonly used diabetes drugs with pancreatic cancer risk

ndividuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida. [More]
GLP-1 pancreatitis concerns justified

GLP-1 pancreatitis concerns justified

Study results have raised further concerns over a link between pancreatitis and the use of glucagon-like peptide-1 (GLP-1)-based therapies for patients with Type 2 diabetes. [More]
GLP-1 may increase risk of hospitalization for people with acute pancreatitis

GLP-1 may increase risk of hospitalization for people with acute pancreatitis

People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report. [More]

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise. [More]
Five prominent surgeons receive Honorary Fellowship from ACS

Five prominent surgeons receive Honorary Fellowship from ACS

Last night Honorary Fellowship in the American College of Surgeons (ACS) was awarded to five prominent surgeons from Japan, the Philippines, Mexico, England, and Belgium during Convocation ceremonies that preceded the official opening of the 2012 ACS Annual Clinical Congress. [More]
NFAT protein plays a part in development of acute pancreatitis

NFAT protein plays a part in development of acute pancreatitis

It is likely that the protein is also highly significant for other inflammatory diseases. The research results have been published in the American journal Gastroenterology. [More]

Well-known protein plays central role in development of acute pancreatitis

There is now a clear target for the treatment of acute pancreatitis, according to researchers at Lund University in Sweden, who have discovered that a well-known protein plays a central role in the development of the disease. It is likely that the protein is also highly significant for other inflammatory diseases. [More]
LPL deficiency treatment poised to be first gene therapy in Europe

LPL deficiency treatment poised to be first gene therapy in Europe

For the first time, the European Medicines Agency has recommended gene therapy for approval in Europe. [More]
Acute pancreatitis: An interview with Viktor Oskarsson

Acute pancreatitis: An interview with Viktor Oskarsson

Acute pancreatitis is an inflammatory disease of the pancreas. The most common symptom is acute abdominal pain, which is often accompanied with nausea and vomiting. [More]
Acute pancreatitis may be staved off by diet rich in vegetables

Acute pancreatitis may be staved off by diet rich in vegetables

A diet rich in vegetables could help stave off the development of the serious condition acute pancreatitis, suggests a large study published online in the journal Gut. [More]
IL-6 protein plays a pivotal role in the duration of acute pancreatitis

IL-6 protein plays a pivotal role in the duration of acute pancreatitis

Scientists from the Universities of Illinois and California have found that the inflammatory protein interleukin-6 (IL-6) plays a pivotal role in the duration of acute pancreatitis in animal models with this condition. [More]
Data from Purdue Pharma’s Butrans clinical trials to be presented at APS annual meeting

Data from Purdue Pharma’s Butrans clinical trials to be presented at APS annual meeting

Purdue Pharma L.P. will present an analysis of data from completed clinical trials for Butrans® (buprenorphine) Transdermal System CIII at the American Pain Society's (APS) 31st Annual Scientific Meeting. [More]
Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy. [More]
Indomethacin given after digestive diagnostic procedure may prevent pancreatitis: Study

Indomethacin given after digestive diagnostic procedure may prevent pancreatitis: Study

There is a high risk of pancreatitis after a diagnostic procedure - ERCP (endoscopic retrograde cholangiopancreatography). ERCP is a procedure that is commonly utilized to treat or diagnose problems of the bile and pancreatic ducts. During an ERCP procedure, a lighted scope is inserted through the mouth while X-ray pictures are taken to check the tubes that drain the liver, pancreas and gallbladder. [More]
European Commission grants marketing authorization for use of BYETTA with basal insulin

European Commission grants marketing authorization for use of BYETTA with basal insulin

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced today that the European Commission has granted marketing authorization to BYETTA (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. [More]

Endoscopic transgastric necrosectomy associated with lower risk of major complications

In a small, preliminary trial, patients with infected necrotizing pancreatitis who received a less-invasive procedure, endoscopic transgastric necrosectomy, had an associated lower risk of major complications and death compared to patients who had surgical necrosectomy, according to a study in the March 14 issue of JAMA. [More]

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. [More]